Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: Experience of the International Society of pediatric oncology, malignant mesenchymal tumors (SIOP-MMT) Working Group

Pediatric Blood and Cancer

Volumn 57, Issue 7, 2011, Pages 1130-1136

  Orbach, Daniel ^a   McDowell, Heather ^b   Rey, Annie ^c   Bouvet, Nathalie ^c   Kelsey, Anna ^d   Stevens, Mike C ^e  

^a INSTITUT CURIE   (France)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^e Royal Hospital for Children   (United Kingdom)

Author keywords

Adolescence; Chemotherapy; Childhood; Radiotherapy; Surgery; Synovial sarcoma

Indexed keywords

DACTINOMYCIN; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD; SYNOVIAL SARCOMA; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR BIOPSY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; SARCOMA, SYNOVIAL; TREATMENT OUTCOME;

EID: 80053898254     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23138     Document Type: Article

References (36)

1. Raney RB. Synovial sarcoma in young people: Background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol 2005; 27: 207-211.
2. Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: An analysis of 1268 patients. Cancer 2009; 115: 3537-3547.
3. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: Identification of low and high risk groups. Cancer 1999; 85: 2596-2607.
4. Machen SK, Easley KA, Goldblum J.R. Synovial sarcoma of the extremities: A clinicopathologic study of 34 cases, including semi-quantitative analysis of spindled, epithelial, and poorly differentiated areas. Am J Surg Pathol 1999; 23: 268-275.
5. Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in childhood and adolescence: A retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr 2010; 55: 85-90.
6. Ferrari A, Bisogno G, Alaggio R, et al. Synovial sarcoma of children and adolescents: The prognostic role of axial sites. Eur J Cancer 2008; 44: 1202-1209; [Epub 2008 Apr 25].
7. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis. J Clin Oncol 2004; 22: 4040-4050; [Epub 2004 Sep 13].
8. Sun Y, Sun B, Wang J, et al. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci 2009; 100: 1018-1025; [Epub 2009 Mar 25].
9. Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome. J Clin Oncol 2003; 21: 1602-1611.
10. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: A multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140.
11. Kampe CE, Rosen G, Eilber F, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer 1993; 72: 2161-2169.
12. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-2511.
13. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101: 627-634.
14. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2, 185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
15. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338; [Epub 2009 Mar 30].
16. Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. J Clin Oncol 2009; 27: 5350-5355; [Epub 2009 Oct 13].
17. Ridola V, Fawaz O, Aubier F, et al. Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophosphamide-based regimens. Eur J Cancer 2009; 45: 814-818; [Epub 2009 Feb 11].
18. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 2009; 52: 108-112.
19. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998; 34: 1050-1062.
20. Stevens MC. Treatment for childhood rhabdomyosarcoma: The cost of cure. Lancet Oncol 2005; 6: 77-84.
21. Donaldson SS, Draper GJ, Flamant F, et al. Topography of childhood tumors: Pediatric coding system. Pediatr Hematol Oncol 1986; 3: 249-258.
22. Rodary C, Flamant F, Donaldson SS. An attempt to use a common staging system in rhabdomyosarcoma: A report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med Pediatr Oncol 1989; 17: 210-215.
23. Lawrence W, Jr., Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: A report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer 1997; 80: 1165-1170.
24. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
25. Andrassy RJ, Okcu MF, Despa S, et al. Synovial sarcoma in children: Surgical lessons from a single institution and review of the literature. J Am Coll Surg 2001; 192: 305-313.
26. Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: Discussion on the role of adjuvant therapies. Pediatr Blood Cancer 2006; 46: 11-17.
27. Okcu MF, Despa S, Choroszy M, et al. Synovial sarcoma in children and adolescents: Thirty three years of experience with multimodal therapy. Med Pediatr Oncol 2001; 37: 90-96.
28. Blakely ML, Spurbeck WW, Pappo AS, et al. The impact of margin of resection on outcome in pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Pediatr Surg 1999; 34: 672-675.
29. Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: The St Jude Children's Research Hospital experience. J Clin Oncol 1994; 12: 2360-2366.
30. Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence. Report of the German CWS-81 study. Cancer 1993; 71: 3647-3655.
31. Ryan JR, Baker LH, Benjamin RS. The natural history of metastatic synovial sarcoma: Experience of the Southwest Oncology group. Clin Orthop Relat Res 1982; 164: 257-260.
32. Shiu MH, McCormack PM, Hajdu SI, et al. Surgical treatment of tendosynovial sarcoma. Cancer 1979; 43: 889-897.
33. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
34. Pratt CB, Pappo AS, Gieser P, et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. J Clin Oncol 1999; 17: 1219.
35. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-1315.
36. Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-160.